The Journal of Urology
Volume 181, Issue 4 , Pages 1642-1657 , April 2009

Use of 5α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

References 

  1. Chlebowski RT, Sayre J, Frank-Stromborg M, et al. Current attitudes and practice of American Society of Clinical Oncology-member clinical oncologists regarding cancer prevention and control. J Clin Oncol. 1992;10:164
  2. Ganz PA, Kwan L, Somerfield MR, et al. The role of prevention in oncology practice: Results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol. 2006;24:2948
  3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371
  4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652
  5. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215
  6. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727
  7. AUA guideline on management of benign prostatic hyperplasia: (2003) (Chapter 1: Diagnosis and treatment recommendations). J Urol. 2003;170:530
  8. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434
  9. Kaplan S, Garvin D, Gilhooly P, et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride: The Pless Study Group. Urology. 2000;56:610
  10. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387
  11. Klein EA, Tangen CM, Goodman PJ, et al. Assessing benefit and risk in the prevention of prostate cancer: The prostate cancer prevention trial revisited. J Clin Oncol. 2005;23:7460
  12. Talcott JA. Rebalancing ratios and improving impressions: Later thoughts from the prostate cancer prevention trial investigators. J Clin Oncol. 2005;23:7388
  13. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172:1314
  14. Wilt T, MacDonald R, Hagerty K, et al. 5-Alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Sst Rev. 2008;issue 2, art. No. CD007091. doi: 10.1002/14651858.CD007091.
  15. Lippman SM, Levin B, Brenner DE, et al. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol. 2004;22:3848
  16. Welch HG. Should I Be Tested for Cancer? (Maybe Not and Here's Why). In: Berkeley, CA: University of California Press; 2004;p. 51–65
  17. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375
  18. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1366
  19. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev Res. 2008;1:174
  20. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128
  21. Lucia MS, Darke AK, Goodman PJ, et al: Pathologic characteristics of cancers detected in the prostate cancer prevention trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res [epub ahead of print on May 18, 2008].
  22. Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163:496
  23. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1025
  24. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119
  25. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia: Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335:533
  26. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: A randomised controlled trial. Lancet Oncol. 2007;8:21
  27. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529
  28. Thompson IM, Pauler Ankerst D, Chi C, et al. Prediction of prostate cancer for patients receiving finasteride: Results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007;25:3076
  29. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:1152
  30. Zuger A. A big study yields big questions. N Engl J Med. 2003;349:213
  31. Svatek RS, Lee JJ, Roehrborn CG, et al. The cost of prostate cancer chemoprevention: A decision analysis model. Cancer Epidemiol Biomarkers Prev. 2006;15:1485
  32. Zeliadt SB, Etzioni RD, Penson DF, et al. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005;118:850
  33. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175:217;discussion 220.
  34. Paick SH, Meehan A, Lee M, et al. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: Results from the Proscar Long-Term Efficacy and Safety Study. J Urol. 2005;173:903
  35. Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61:579
  36. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial (PLESS Study Group—Proscar Long-Term Efficacy and Safety Study). Urology. 1998;52:195;discussion 201.
  37. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia: Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557
  38. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537;discussion 542.
  39. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82
  40. O'Leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003;92:262
  41. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study)—PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ. 1996;155:1251
  42. Johnson TM, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: Secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol. 2003;170:145
  43. Cote RJ, Skinner EC, Salem CE, et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer. 1998;78:413
  44. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43:284;discussion 292.
  45. Stoner E. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia: The Finasteride Study Group. Arch Intern Med. 1994;154:83
  46. Stoner E, Round E, Ferguson D, et al. Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride: The Finasteride Study Group. J Urol. 1994;151:1296
  47. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia: The Finasteride Study Group. N Engl J Med. 1992;327:1185
  48. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia: The Finasteride Study Group. Prostate. 1993;22:291
  49. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179
  50. Rigatti P, Brausi M, Scarpa RM, et al. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2003;6:315
  51. Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. J Int Med Res. 2002;30:584

 Approved by the American Society of Clinical Oncology Board on July 21, 2008, and by the American Urological Association Board on October 17, 2008.

 This document is being reprinted as submitted without editorial or independent peer review by the Editors of The Journal of Urology®.

 This guideline was developed through a collaboration between the American Society of Clinical Oncology and the American Urological Association, and has been published jointly by invitation and consent in the Journal of Clinical Oncology and The Journal of Urology®. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology or the American Urological Association.

 See Editorial on page 1530.For another article on a related topic see page 1907.

PII: S0022-5347(09)00172-4

doi: 10.1016/j.juro.2009.01.071

The Journal of Urology
Volume 181, Issue 4 , Pages 1642-1657 , April 2009

Article Tools

* Image Usage & Resolution